Showing results (171-180 of 286) with videos related to
Sort By:
Pageof 29
Journal for Immunotherapy of Cancer|May 4, 2023
Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II trialJason A Chesney, Igor Puzanov, Frances A Collichio, et al.The Lancet. Oncology|March 30, 2012
Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trialKim Margolin, Marc S Ernstoff, Omid Hamid, et al.Cancer|March 29, 2014
A randomized, open-label clinical trial of tasisulam sodium versus paclitaxel as second-line treatment in patients with metastatic melanomaOmid Hamid, Robert Ilaria, Claus Garbe, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 13, 2016
Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia StudyDavid F McDermott, Jeffrey A Sosman, Mario Sznol, et al.Scientific Reports|April 23, 2021
Transcriptomic analysis identifies differences in gene expression in actinic keratoses after treatment with imiquimod and between responders and non respondersMegan H Trager, Emanuelle Rizk, Sharon Rose, et al.Journal for Immunotherapy of Cancer|January 20, 2018
Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trialHoward L Kaufman, Jeffery S Russell, Omid Hamid, et al.Investigational New Drugs|August 7, 2019
Phase I study of the anti-endothelin B receptor antibody-drug conjugate DEDN6526A in patients with metastatic or unresectable cutaneous, mucosal, or uveal melanomaShahneen Sandhu, Catriona M McNeil, Patricia LoRusso, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 29, 2018
Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037)Tara C Mitchell, Omid Hamid, David C Smith, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 9, 2025
Phase II Open-Label Trial of Brentuximab Vedotin with Pembrolizumab in PD-1-Pretreated Metastatic Non-Small Cell Lung Cancer and Metastatic Cutaneous MelanomaSylvia M Lee, Omid Hamid, Robert Jotte, et al.The Lancet. Oncology|July 20, 2014
Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b studyAntoni Ribas, Rene Gonzalez, Anna Pavlick, et al.Pageof 29